Drug Development

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

Voyager Therapeutics' new gene therapy just cleared a key FDA hurdle. With promising preclinical data, it's a major momentum signal in the fight against Alzheimer's.

After an initial rejection, Sydnexis's pediatric myopia drug gets a crucial FDA hearing, raising hopes for the first approved U.S. pharmaceutical treatment.

By hiring top drug and deal makers, Bexorg signals its AI-powered human brain platform is ready to move from a bold experiment to a commercial powerhouse.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

A Utah biotech is deploying UAE genomics and a novel drug to mimic natural immunity to Alzheimer's, signaling a strategic shift to precision prevention.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.

A Swiss biotech's oral drug just showed it can cross into the human brain and alter its activity, a key de-risking step in a high-stakes pivot.

A novel drug, LM11A-31, paired with advanced brain mapping, shows promise by preserving neural networks, marking a potential shift from targeting plaques.

Backed by $180M, Celea Therapeutics is deploying a bold head-to-head superiority trial, aiming to prove its drug isn't just an alternative but a new standard.

This Monday, Q32 Bio will unveil pivotal data for its alopecia areata drug. For 700,000 Americans, it could mean a new path beyond today's treatments.

A mining firm just secured a key gene therapy patent for ALS. Timothy Bell dissects the audacious strategy of funding cutting-edge biotech with Greenland's mineral wealth.

The Novo Nordisk Foundation's record €80M grant program isn't just charity. It's a calculated move to reshape European science and tackle crises from soil health to obesity.

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

Rani Therapeutics partners with PegBio, betting its drug-injecting capsule can unlock novel oral obesity therapies and challenge market giants.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Amplia Therapeutics' new patent application for novel FAK inhibitors extends protection to 2046, signaling a major play in oncology and fibrosis markets.